Our Liposomal Glutathione is designed for simple daily use
Another systematic review from 2025 reported conflicting findings, with some participants even experiencing hair regrowth
Side effects are rare and usually mild, including minor bruising or discomfort at the injection site
This issue came to the fore in early 2024 when the UK MHRA issued a National Patient Safety Alert triggered by global supply issues for certain GLP-1 drugs, advising healthcare professionals to conserve existing stock for patients with Type 2 diabetes.6,7 The implementation of such measures ensures that the critical priority of patient needs continues to be met, while also avoiding patients seeking what the WHO describes as falsified or substandard versions of these medicines through unregulated outlets on the internet.8 Looking to the future, demand for GLP-1 drugs is expected to remain high as healthcare systems look to manage obesity and diabetes among an ageing population
However, for Wegovy (specifically FDA-approved for weight loss), the window is often shorter, usually cited as 2 days
Tirzepatide, the first approved dual GIP/GLP-1 receptor agonist, is a 39-amino acid peptide with an approximately 120-hour half-life supporting once-weekly dosing
